Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is focusing on the development and commercialization of innovative treatments of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Strategically, Santhera focuses on RaxoneŽ/CatenaŽ (INN: idebenone) in mutliple indications.
Read more about Santhera

Products & Pipeline

Santhera has a late-stage development pipeline in orphan indications. The lead compound RaxoneŽ/CatenaŽ (INN: idebenone) is being developed in three indications: Leber's Hereditary Optic Neuropathy, Duchenne Muscular Dystrophy, and Primary Progressive Multiple Sclerosis.

Learn more about our products and pipeline

Clinical Development Programs

Currently, the NIH are investigating the safety and efficacy of RaxoneŽ/CatenaŽ in a Phase II trial (IPPoMS) as potential therapy of primary progressive Multiple Sclerosis. Also at the NIH, a Phase I study (CALLISTO) is being initiated to investigate the omigapil in pediatric and adolescent patients suffering from Congenital Muscular Dystrophy.
Learn more about Santhera's clinical trials

Latest News

March 11, 2015
Principal Investigator to Present Phase III Data on Idebenone in Duchenne Muscular Dystrophy (DMD) at the Annual Meeting of the American Academy of Neurology (AAN)
January 30, 2015
Santhera Extends Executive Management and Appoints Chief Commercial Officer
January 23, 2015
Santhera reports preliminary key financial figures for 2014